Factory Supply Dapagliflozin Powder CAS 461432-26-8 with Good Price
Product Description
Dapagliflozin (ForxigaTM) is a new antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, being approved by the European Medicines Agency (EMA) on November 12, 2012. It is also the first approved SGLT2 inhibitor for the treatment of type II diabetes, being an important option in the treatment of diabetes, and is used to improve glycemic control as an adjunct to dietary and exercise for adults with type II diabetes.
| Product name | Dapagliflozin |
| CAS | 461432-26-8 |
| Appearance | white powder |
| Assay | 99% |
| Storage | Cool and Protect from light |
Function and Application
Dapagliflozin is a drug used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.Although dapagliflozin's method of action would operate on both types of diabetes and other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with type 1 diabetes.
